Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5459)
All Articles published online
|
Publishing Process of This Article
|
Jun 26, 2014 (publication date) through Feb 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Methodology
ISSN
2222-0682
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Colloca G, Venturino A, Governato I. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol 2014; 4(2): 123-132 [PMID: 25332911 DOI: 10.5662/wjm.v4.i2.123] |
|---|---|
| URL: | https://www.wjgnet.com/2222-0682/full/v4/i2/123.htm |
| Number | Citing Articles |
| 1 |
Matthew Rashid, Eli Oldham, Griffin K. Hughes, Andriana M. Peña, Chase Ladd, Brooke Gardner, Ryan McIntire, Bradley Johnson, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Abiraterone Clinical Trials. Journal of Urologic Oncology 2024; 22(3): 211 doi: 10.22465/juo.244800520026
|
| 2 |
William K. Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y. Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clinical Genitourinary Cancer 2018; 16(1): 50 doi: 10.1016/j.clgc.2017.06.004
|